Last reviewed · How we verify
Cancer vaccine plus immune adjuvant
Cancer vaccine plus immune adjuvant is a Biologic drug developed by TVAX Biomedical. It is currently in Phase 1 development.
At a glance
| Generic name | Cancer vaccine plus immune adjuvant |
|---|---|
| Sponsor | TVAX Biomedical |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma (PHASE2)
- Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ (PHASE1)
- RNA Lipid Particles Targeting Pediatric Recurrent Intracranial Malignancies and Other systEmic Solid Tumors (PHASE1, PHASE2)
- Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor (PHASE3)
- A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma (PHASE2)
- Expanded Access To Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors
- Pseudovax - A Cancer Vaccine for Patients With Pseudomyxoma Peritonei (EARLY_PHASE1)
- BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cancer vaccine plus immune adjuvant CI brief — competitive landscape report
- Cancer vaccine plus immune adjuvant updates RSS · CI watch RSS
- TVAX Biomedical portfolio CI
Frequently asked questions about Cancer vaccine plus immune adjuvant
What is Cancer vaccine plus immune adjuvant?
Cancer vaccine plus immune adjuvant is a Biologic drug developed by TVAX Biomedical.
Who makes Cancer vaccine plus immune adjuvant?
Cancer vaccine plus immune adjuvant is developed by TVAX Biomedical (see full TVAX Biomedical pipeline at /company/tvax-biomedical).
What development phase is Cancer vaccine plus immune adjuvant in?
Cancer vaccine plus immune adjuvant is in Phase 1.